Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

NCT00006368 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Brain and Central Nervous System Tumors
Breast Cancer
Gastrointestinal Carcinoid Tumor
Islet Cell Tumor
Lung Cancer
Lymphoma
Melanoma (Skin)
Neoplastic Syndrome

Interventions

RADIATION: yttrium Y 90-edotreotide

Sponsor

Novartis Pharmaceuticals